Evidence map›Paper›PMID 35156519›Full record

ArticleAutophagy2022

Clinical trial results show promise of targeting autophagy

Ravi K Amaravadi

Open access · greenAbstract readComment
In one paragraph

Article in Autophagy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Autophagy in Melanoma: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Oral Carbon Monoxide Enhances Autophagy Modulation in Prostate, Pancreatic, and Lung Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ravi K AmaravadiAbramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Targeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2021 to 2025
$11.3M
Targeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1M
Resistance mechanisms to autophagy-modulating therapiesR01CA266404 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RAVI K AMARAVADI, Aaron Robert Goldman · 2022 to 2026
$3.2M
NCI NIH HHS P30 CA016520NCI NIH HHS P50 CA174523NCI NIH HHS P50 CA261608
6 · The paper itself

Abstract

Macroautophagy/autophagy is a resistance mechanism to targeted therapy in

Indexed as

MelanomaSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAutophagyClinical Trials as TopicHumansHydroxychloroquineMutationProto-Oncogene Proteins B-rafPyrimidinonesBRAF protein, humanHydroxychloroquineProto-Oncogene Proteins B-rafPyrimidinonesAutophagyclinical trialhydroxychloroquinemelanomatargeted therapy

Identifiers

PMID35156519
PMCPMC9225520
OpenAlexW4212938300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.